Cargando...
Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers
INTRODUCTION: Immune checkpoint inhibitors (ICIs) are approved in multiple indications for cancer care. Most of the clinical trials have not questioned shorter than until disease progression approaches. In this study, we present results from a cohort of multiple advanced cancers treated with restric...
Gardado en:
| Publicado en: | J Cancer Res Clin Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer Berlin Heidelberg
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7324422/ https://ncbi.nlm.nih.gov/pubmed/32306129 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-020-03217-7 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|